ABSTRACT
This project reviewed gene mutations which are associated with BRCA1 and BRCA2. From epidemiological perspective, the escalating cost of breast cancer management is due to the aging phenomenon of the female cohort in United States population. Innovative genomic sequencing techniques could continue to augment gene mutations beside the BRCA1/BRCA2 and TP53, PTEN, ST11/LKB1, CDH1, CHEK2, and ATM among others. To reduce the escalating cost of breast cancer management, the application of pharmacogenomic techniques, use of electronic health record and the most appropriate software could be applied for both primary prevention and chemoprevention. Physicians and other clinicians must hone their skills in advanced Mendelian genetics to become proficient in using statistical risk analysis and the appropriate IT software to recommend primary prevention to at risk breast cancer patients.